-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Center point: Cancer patients treated with immuno-checkpoint inhibitors have a higher risk of developing venous and arterial thromboembolism.
venous thromboembolism under the action of immunosuppressants seriously affects clinical prognosis and is difficult to predict.
: Currently, the risk of venous and arterial thromboembolism (VTE/ATE) associated with immuno checkpoint inhibitors is not fully identified, and clinical trials to evaluate such drugs in cancer patients do not provide relevant information.
the study aims to quantify the risk of VTE/ATE in a group of patients treated with immuno-checkpoint inhibitors, to explore its clinical impact, and to study potential clinical risk factors.
Used internal pharmacy records to screen 672 patients treated with immuno-checkpoint inhibitors at the Medical University of Vienna in 2015-2018, the most common types of tumors: melanoma (30.4%), non-small cell lung cancer (24.1%), and stage IV tumors (86%).
VTE and/or ATE are screened using retrospective methods.
the cumulative rate and intergroup differences within the framework of competitive risk.
use multi-state modeling to study the effects of VTE/ATE on mortality.
the cumulative occurrence of VTE and ATE was more than 8.5 months, with a total of 47 VTE and 9 ATEs.
of VTE and ATE were 12.9% and 1.8%, respectively.
the occurrence of VTE, which is associated with prognosm, was associated with an increase in mortality (transition risk ratio .THR 3.09).
the occurrence of predictable VTE in the history of VTE (sub-distribution risk ratio of sHR 3.69), there is no significant correlation between distant transfer and VTE risk (SHR 1.71).
no correlation between VTE and ECOG performance status, Charlson-combined index, or Khorana score was observed, and the incidence of VTE was comparable between different cancer species and different immuno-checkpoint inhibitors.
, cancer patients treated with immuno-checkpoint inhibitors had a higher risk of thromboembolism, especially VTE.
, VTE occurs in correlation with increased mortality risk.
.
